新药替卡格雷与普拉格雷及其克服氯吡格雷抵抗的研究进展

New drugs ticagrelor and prasugrel and the study progress on the aspect of their anti-clopidogrel resistance acitivity

目的对新型抗血小板凝集药普拉格雷和替卡格雷及它们与原有抗血小板聚集药氯吡格雷的异同及克服氯吡格雷抵抗作用进行综述。方法参阅最新国内外公开发表的相关文献,阐述新药普拉格雷和替卡格雷的研发思路及作用特点,比较它们与原有抗血小板聚集药氯吡格雷的异同,论述其克服氯吡格雷抵抗的作用机制所在。结果相对于氯吡格雷,新型抗血小板聚集药普拉格雷和替卡格雷更加强力有效,并可明显降低甚至避免氯吡格雷抵抗事件的发生。结论国际知名制药公司对普拉格雷和替卡格雷的研发理念可带给我们新启示,这些新型抗血小板聚集药为临床医师提供了新的用药选择。

Objective To introduce the development of prasugrel and ticagrelor which were new antiplateletdrugs, as well as the difference between them and the primary anti-platelet drug clopidogrel and demonstrate that clopidogrel resistance can be overcome by the two drugs. Methods The review was completed based on the latest published literatures. Some research developing ideas and the action characters of prasugrel and ti- cagrelor were presented. Moreover, pharmacological effects and pharmacokinetic properties of the new drugs and clopidogrel were compared, and the mechanism of the drugs overcoming clopidogrel resistance was also discussed in this review. Results The two new drugs had a stronger potency comparing with clopidogrel and could significantly reduce the occurrence of clopidogrel resistance. Conclusions The developing ideas of pra- sugrel and ticagrelor can provide us with new enlightenments. In addition, these new anti-platelet drugs can also offer new choices for clinician.